Dr. Martens (LON:DOCS) Insider Acquires £49,185.36 in Stock

Dr. Martens plc (LON:DOCS) insider Giles Wilson bought 68,313 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were bought at an average cost of GBX 72 per share, with a total value of £49,185.36.

Giles Wilson also recently made the following trade(s):

• On Thursday, June 11th, Giles Wilson purchased 202 shares of Dr. Martens stock. The shares were bought at an average price of GBX 74 per share, for a total transaction of £149.48.
• On Wednesday, May 13th, Giles Wilson purchased 233 shares of Dr. Martens stock. The stock was bought at an average cost of GBX 64 per share, for a total transaction of £149.12.
• On Tuesday, April 14th, Giles Wilson acquired 232 shares of Dr. Martens stock. The stock was bought at an average price of GBX 65 per share, with a total value of £150.80.

Dr. Martens Stock Down 1.3%

Shares of Dr. Martens stock traded down GBX 0.90 on Friday, reaching GBX 71.10. 714,890 shares of the company were exchanged, compared to its average volume of 8,611,851. The stock’s 50 day moving average price is GBX 68.37 and its 200-day moving average price is GBX 69.35. The company has a debt-to-equity ratio of 108.27, a current ratio of 2.61 and a quick ratio of 1.13. Dr. Martens plc has a 1-year low of GBX 59.15 and a 1-year high of GBX 100.87. The company has a market cap of £680.49 million, a P/E ratio of 29.62, a price-to-earnings-growth ratio of 6.40 and a beta of 0.25.

Dr. Martens (LON:DOCS) last issued its earnings results on Tuesday, May 19th. The company reported GBX 4.20 earnings per share for the quarter. Dr. Martens had a net margin of 3.11% and a return on equity of 6.89%. The firm had revenue of £764.90 million for the quarter. As a group, equities analysts forecast that Dr. Martens plc will post 2.5809394 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on DOCS. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a GBX 100 price objective on shares of Dr. Martens in a research report on Tuesday, June 2nd. Berenberg Bank dropped their target price on Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Dr. Martens has an average rating of “Moderate Buy” and an average target price of GBX 105.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.